Introduction: A prolonged activated partial thromboplastin time (APTT) may be in-
| INTRODUC TI ON
Activated partial thromboplastin time (APTT) is widely used for the screening of coagulation disorders in the investigation of haemostatic abnormalities, providing a measure of the efficiency of the historically termed intrinsic and common pathways of blood coagulation. A prolonged APTT may be an indicator of a specific or multiple factor deficiency, the presence of a factor-specific inhibitor, therapeutic anticoagulation or the presence of a nonspecific inhibitor or lupus anticoagulant (LA).
1 Some algorithms to investigate an APTT prolongation in clinical laboratory have been proposed. 1, 2 Lupus anticoagulants are phospholipid-dependent antibodies that interfere with one or more in vitro coagulation reactions, which are dependent on interactions with protein-phospholipid complexes. As a result of the involvement of phospholipids in these epitopes, LA are grouped in the antibody family that is known as antiphospholipid antibodies (aPL). 3 When laboratory assays demonstrate the presence of persistent aPL in patients with thrombosis or pregnancy morbidity, the patients are diagnosed as having antiphospholipid syndrome (APS). 4 On the other hand, a deficiency of coagulation factors presents a bleeding risk, although contact factor deficiencies other than factor XI are not associated with a bleeding tendency but can elevate APTT. Coagulation inhibitors, such as 
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• 6 from Factor VIII low activity (<1%, 1%, 2%, 5%, 10%, 20%) • 6 from Factor IX low activity (<1%, 1%, 2%, 5%, 10%, 20%) • 6 from Factor XI low activity (<1%, 1%, 2%, 5%, 10%, 20%) • 6 from Factor XII low activity (<1%, 1%, 2%, 5%, 10%, 20%)
Artificially common pathway factor deficiencies 17
• 5 from Factor II low activity (1%, 2%, 5%, 10%, 20%) • 6 from Factor V low activity (<1%, 1%, 2%, 5%, 10%, 20%) • 6 from Factor X low activity (<1%, 1%, 2%, 5%, 10%, 20%) TA B L E 1 Detailed information for the plasma samples acquired haemophilia A, are rare and are associated with bleeding complications that can be severe or even life threatening. 5 Although these disparate disorders show APTT prolongation, the treatments are different and thus it is crucial to further investigate the cause of APTT prolongation to achieve diagnostic resolution.
Commercial APTT reagents are composed of contact pathway activators, such as silica or ellagic acid, along with various phospholipids. The sensitivity and specificity of APTT reagents to heparin, LA and coagulation factor deficiencies vary because of differences in activators employed, as well as the source, composition and total concentrations of phospholipids. 6, 7 Especially, the sensitivity of APTT reagents for LA is dependent on the phospholipid composition and concentration, and not the activator. 8 The characteristics of APTT reagents are utilised for differentiating the cause of APTT prolongation. Adding a LA-insensitive APTT sequentially to a prolonged LA-sensitive APTT can distinguish between the presence of LA and coagulation factor deficiency. 9, 10 In addition, a screening test and confirmatory test in an APTT based assay are recommended in LA guidelines. 4, 11, 12 Recently, the LA-sensitive and standard APTT reagent pair, Cephen LS and Cephen (Hyphen BioMed, Neuville-sur-Oise, France), respectively, was shown to be useful for LA detection. 13 The present study aimed to evaluate the utility of the Cephen LS/Cephen pair for the differentiation of causes of APTT prolongation. We also com- 
| MATERIAL S AND ME THODS

| Plasma samples
Sample preparation methods were performed as described pre- Six samples with low coagulation activity were prepared for each factor to concentrations of <1%, 1%, 2%, 5%, 10% and 20%. The factor II sample <1% was excluded from the data analysis because of a coagulation error on the analyser. Reference ranges were generated from 50 commercially sourced, frozen normal donor plasmas, CRYOcheck Normal Donor Set (Precision BioLogic Inc, Dartmouth, Canada). The plasmas were prepared to be sufficiently platelet poor for LA testing and were checked to be LA-negative by the manufacturer. These tests were performed in a CS-2400 (Sysmex Corporation, Kobe, Japan).
| Coagulation screening tests
| Reference intervals and cut-off values
Cut-off values in the screen ratio of Cephen LS and LA1 screening reagent were previously established locally as 1.09 and 1.12 by calculating the upper limits of the distribution of 50 normal samples, respectively. 4, 11, 12, 16 The cut-off value of percent correction was already established and 10% was used in each reagent pair.
4,12-16
| Statistical analysis
Samples deemed LA-positive from analysis with the routine reagents were tested with Cephen LS/Cephen and LA1/LA2 and divided into 3 groups: group 1 was defined as normal screen ratio and LA not detected; group 2 showed elevated screen ratio but <10% correction by confirm reagent and LA not detected; and group 3 showed elevated screen ratio and more than 10% correction by confirm ratio and LA detected. A Mann-Whitney U test was used to compare the data for the various parameters. P < 0.05 was considered statistically significant.
| RE SULTS
| The characteristics of LA-positive samples
Plasmas were classified into 3 groups according to reactivity with the various reagents ( Table 2 ). Groups 1, 2 and 3 contained, respectively, 43, 29 and 33 samples, tested with Cephen and Cephen LS ( Table 2 ). ans of screen ratios, as well as percent correction in group 3, were higher than those of group 2, respectively. In addition, the number of plasmas assigned to groups 1, 2 and 3 from LA1/LA2 testing was 39, 2 and 64, respectively, and means and median screen ratios, as well as percenateg correction in group 3, were higher than those in group 2. Sixty-six samples in groups 2 and 3 out of 105 (62.9%) had an elevated screen ratio with LA1, and 64 in group 3 were confirmed as LA via ≥10% correction with LA2.
| Comparison between the LA-positive group and other groups
The dAPTT/dRVVT positive group were significantly higher than those from all other groups, including dAPTT-and dRVVT-only positive. Between-group data comparisons via a Mann-Whitney U test are shown in Table 3 . In dAPTT-and dRVVT-only positive groups, the values of these groups were significantly higher than those for the intrinsic pathway deficiencies, common pathway deficiencies, APTT elevated, factor-specific inhibitor and warfarin groups, and they showed no significant difference with respect to normal and APTT-elevated and factor-specific inhibitor groups. Furthermore, the values were statistically significantly lower than those of the warfarin group. Overall, the medians of the dAPTT/dRVVT positive and dRVVT-only positive groups were higher than the 10% cut-off value in LA1/LA2 and showed good sensitivity. However, the values of warfarin group were similar to those of the dAPTT/dRVVT positive and dRVVT-only positive groups and were not statistically significantly different.
| Positivity in LA double positive samples
The percent positive of Cephen LS/Cephen and LA1/LA2 pairs was assessed in samples double positive with respect to the dAPTT and dRVVT reagents used in the routine testing (Table 4 ). There were 
| D ISCUSS I ON
In the present study, we evaluated the usefulness of the Cephen LS/ Cephen pairing for differentiation of causes of APTT prolongation, and also investigated the sensitivity to LA and the utility for differentiation of APTT prolongation. In addition, the performance characteristics were assessed when partnered with the LA1/LA2 dRVVT reagent pair. One hundred and five samples from non-anticoagulated patients who were LA-positive with one or both routinely employed dRVVT and dAPTT reagents were used to assess LA sensitivity.
Cephen LS/Cephen showed 33 samples were LA-positive (Table 1) and 11/33 were LA-positive with the routine dRVVT alone. In addition, the median percent correction values for LA-positive in the routine dRVVT/dAPTT and dRVVT-only were higher than that for LA-positive in dAPTT-only, and the median of the dAPTT-only positive group was similar to that of the asymptomatic, normal group ( Figure 1) . Thus, the reactivity with the combination of Cephen LS/ Cephen was higher in dRVVT positive LA samples than with dAPTT alone. Cephen LS is not a dilute APTT for LA detection but it is a routine APTT reagent considered to be LA-sensitive as a function of its phospholipid composition, and so it was useful to compare performance with a dAPTT reagent specifically formulated for LA The P values are shown in each comparison between all groups and LA-positive groups. LA-positive groups included dAPTT/dRVVT positive, dAPTT and dRVVT-only positive. The detailed information for each group is the same as indicated in Table 1 . Asterisk means the statistically significant. There was high diagnostic concordance between the routine dRVVT reagents and the LA1/LA2 pair and previous studies have shown that the performance variation was not large between most commercial dRVVT reagents. 16, 17 Depreter and Devreese 18 previously reported that clotting times with dRVVT screening and confirmation reagents were prolonged for moderately decreased FII and FX levels (40%-60%) and mildly decreased FV (70%). 18 In the present study, percent correction was A major problem with dRVVT analysis is that warfarin therapy causes false positives. 19 Recently, newly developed dRVVT reagents were reported to exhibit improved specificity as a result of less discordance between screens and to confirm results in samples from patients anticoagulated with vitamin K antagonists and direct oral anticoagulants. 18, 20 The dRVVT reagents used in the present study were affected by warfarin because the median percent correction in the warfarin group was similar to that of the dRVVT/dAPTT positive group and it was considered that LA1/LA2 showed a high false positive rate with these patients (Figure 1 According to earlier BSH guidelines, we adopted 10% as the cut-off value in percent correction for Cephen LS/Cephen assay in the present study. 12 Although current guidelines recommend local derivation, this cut-off value has been validated both locally [14] [15] [16] 20 and in a multicentre study 22 
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